Prof. Dr. Andreas Zimmer
Institute of Molecular Psychiatry (IMP)
neuro@uni-bonn.de View member: Prof. Dr. Andreas Zimmer
ACS pharmacology & translational science
Brain aging is associated with cognitive decline, reduced synaptic plasticity, and altered metabolism. The activity of mechanistic target of rapamycin (mTOR) has a major impact on aging by regulating cellular metabolism. Although reduced mTOR signaling has a general antiaging effect, it can negatively affect the aging brain by reducing synaptogenesis and thus cognitive functions. Increased mTOR activity facilitates aging and is responsible for the amnestic effect of the cannabinoid receptor 1 agonist Δ-tetrahydrocannabinol (THC) in higher doses. Long-term low-dose Δ-THC had an antiaging effect on the brain by restoring cognitive abilities and synapse densities in old mice. Whether changes in mTOR signaling and metabolome are associated with its positive effects on the aging brain is an open question. Here, we show that Δ-THC treatment has a tissue-dependent and dual effect on mTOR signaling and the metabolome. In the brain, Δ-THC treatment induced a transient increase in mTOR activity and in the levels of amino acids and metabolites involved in energy production, followed by an increased synthesis of synaptic proteins. Unexpectedly, we found a similar reduction in the mTOR activity in adipose tissue and in the level of amino acids and carbohydrate metabolites in blood plasma as in animals on a low-calorie diet. Thus, long-term Δ-THC treatment first increases the level of energy and synaptic protein production in the brain, followed by a reduction in mTOR activity and metabolic processes in the periphery. Our study suggests that a dual effect on mTOR activity and the metabolome could be the basis for an effective antiaging and pro-cognitive medication.
© 2024 The Authors. Published by American Chemical Society.
PMID: 39296258
Institute of Molecular Psychiatry (IMP)
neuro@uni-bonn.de View member: Prof. Dr. Andreas Zimmer